Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (89)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bowsher, D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bowsher, D
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

British Medical Bulletin 47:644-666 (1991)
© 1991 The British Council

research-article

Neurogenic pain syndromes and their management

D Bowsher

Pain Research Institute, Univsity Department of Neurological Science, Walton Hospital Liverpool, UK

Abstract

Neurogenic pain is defined as pain due to dysfunction of the peripheral or central nervous system, in the absence of nociceptor (nerve terminal) stimulation by trauma or disease. Other terms used to describe some (but not all) forms of neurogenic pain include neuropathic pain, deafferentation pain, and central pain; all these terms are subsumed into the wider expression ‘neurogenic pain’. The clinical syndromes representing this type of disorder make up at least 25% of the patients attending most pain clinics. This is undoubtedly proportionately greater than its incidence in chronic pain as a whole, and is a measure of its intractability and of the therapeutic dilemma which it presents. However, neurogenic pain syndromes are much commoner than is perhaps generally recognized: when all categories are taken into account, there are probably more than 550,000 cases in the UK population of 56 million at any one time, i.e. a prevalence of about 1%.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
M. M. Ibrahim, H. Deng, A. Zvonok, D. A. Cockayne, J. Kwan, H. P. Mata, T. W. Vanderah, J. Lai, F. Porreca, A. Makriyannis, et al.
Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: Pain inhibition by receptors not present in the CNS
PNAS, September 2, 2003; 100(18): 10529 - 10533.
[Abstract] [Full Text] [PDF]

Home page
 Canadian J. AnesthesiaHome page
I. Gilron and J. M. Bailey
Trends in opioid use for chronic neuropathic pain: a survey of patients pursuing enrollment in clinical trials: [Evolution de l'usage des opioides contre la douleur neuropathique chronique : une enquete aupres de patients voulant participer a des essais cliniques]
Can J Anesth, January 1, 2003; 50(1): 42 - 47.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
K. Ramu, G. N. Lam, and H. Hughes
In Vivo Metabolism and Mass Balance of 4-[4-Fluorophenoxy]benzaldehyde Semicarbazone in Rats
Drug Metab. Dispos., October 1, 2000; 28(10): 1153 - 1161.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
P. Wanklyn, A. Forster, J. Young, and G. Mulley
Prevalence and Associated Features of the Cold Hemiplegic Arm
Stroke, October 1, 1995; 26(10): 1867 - 1870.
[Abstract] [Full Text]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.